Ticker: TECH

Bio-Techne

Biotech Healthcare Biotechnology
Price 72.28
Reco Buy Potential 62 Risk 40 Updated 2026-09-09

Forecast impact

neutral
Target +1.0% target fill 99.0%
Reaction D5 -1.33% · D10 -1.69%
Impact Potential 0 · Risk 0 valid until 2026-09-12

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Bio-Techne Corporation operates in the healthcare sector, specializing in the development and manufacturing of biotechnology products and tools. Its core offerings include proteins, antibodies, and reagents used in research and clinical applications. Major business segments consist of Protein Sciences, Diagnostics, and Clinical Diagnostics, with primary revenue sources stemming from sales of research reagents and instruments. The company serves academic, pharmaceutical, and biotechnology markets.

Investment Profile

The investment profile of Bio-Techne is more aligned with balanced investors, given its moderate growth potential and dividend yield. The stock exhibits characteristics suitable for those seeking a mix of capital appreciation and income, though it carries a higher risk profile. Investors may consider a medium to long-term horizon for potential returns, while liquidity remains moderate.

Fundamental metrics (experimental) Updated: 2026-09-08
EPS (TTM) — earnings per share for the last 12 months, $
1.17
Revenue QoQ — quarter-over-quarter revenue growth
3.1%
EPS surprise
0.2%
20d volatility
0.1%
Dividend yield
0.6%
last ex-date
2026-08-24
AI recommendation changes
Date Before After Reason
2026-08-25 Hold Buy Moderate growth with some analyst support, but risks present.
2026-08-14 Buy Hold Mixed momentum; fundamentals show slight weakness.
2026-07-28 Hold Buy Moderate growth, but recent EPS surprise raises concerns.
Analyst forecasts
Date Analyst Action Target Price Then
2026-08-13 Wells Fargo Rating Downgraded — → 73 72.225
2026-06-26 Stephens Rating Downgraded — → 73 71.16
2026-06-26 Robert W. Baird Target Raised 49 → 73 70.7
News Page 1 of 1